Evommune
Last verified 2026-05-20. JSON
| Total raised | $172.5M |
|---|---|
| Latest round | series-d+, $115.0M, 2024-10-01 |
| Founded | 2020 |
| Headquarters | Palo Alto, CA |
| Industry | biotechnology |
| Stage | series-b+ |
| Website | evommune.com |
Evommune is a clinical-stage biotech developing therapies for chronic inflammatory and immune-mediated diseases using a human tissue-based discovery approach. It aims to treat patients with conditions like chronic urticaria and other inflammatory skin and immune disorders. Its tissue-based platform is designed to find drugs that both relieve symptoms and halt disease progression.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-10-01 | series-d+ | $115.0M | undisclosed |
Detected tech stack
Cloudflare, WordPress, Magnific Popup, Yoast SEO 27.4, Google Tag Manager, FitVids.JS, Font Awesome, jQuery Migrate, jQuery Mobile, Easy Pie Chart, Cloudflare Bot Management, Zepto
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series D+, $115.0M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Total raised $172.5M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Company existence | self-reported | evommune.com, read 2026-05-20 |
| Description | self-reported | evommune.com, read 2026-05-20 |
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Round: attributed → sourced, SEC EDGAR, document, retrieved 2026-09-25 | Round | attributed → sourced | SEC EDGAR, document, retrieved 2026-09-25 |
Records begin 2026-09-24. All changes